Stifel Nicolaus Sticks to Its Buy Rating for Inovio Pharmaceuticals

By Ryan Adsit

In a report issued on May 24, Thomas Shrader from Stifel Nicolaus reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ: INO), with a price target of $11. The company’s shares closed yesterday at $7.88.

According to, Shrader is a 4-star analyst with an average return of 13.2% and a 46.5% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Threshold Pharmaceuticals, and Tracon Pharmaceutical.

Currently, the analyst consensus on Inovio Pharmaceuticals is Strong Buy and the average price target is $11.80, representing a 49.7% upside.

In a report issued on May 11, Maxim Group also reiterated a Buy rating on the stock with a $10 price target.

The company has a one year high of $11.62 and a one year low of $5.83. Currently, Inovio Pharmaceuticals has an average volume of 1.28M.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. Last month, Jong Joseph Kim, the Chief Executive Officer of INO sold 147,180 shares for a total of $961,821.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Inovio Pharmaceuticals, Inc. is a bio pharmaceutical company. It develops active DNA immunotherapies for cancer and infectious diseases. The company’s portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. Its pipeline consists vgx-3100, ino-3122, ino-3106, pennvax-b and pennvax-g. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.